A Phase II Open-Label Study of Sorafenib Plus Fulvestrant As Salvage Therapy for Hormone receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Sorafenib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Jul 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Oct 2009 New source identified and integrated (Oregon Health and Science University Cancer Institute).